Previous close | 47.59 |
Open | 47.30 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 47.25 - 47.45 |
52-week range | 42.60 - 69.40 |
Volume | |
Avg. volume | 1,466 |
Market cap | 6.961M |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | 0.36 |
EPS (TTM) | 1.30 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGMCosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting 26.05.2023 / 16:30 GMT/BSTDublin, Ireland – 26 May 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders.A total of 7,512,823 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of shareholders co
Readers hoping to buy Cosmo Pharmaceuticals N.V. ( VTX:COPN ) for its dividend will need to make their move shortly, as...
With its stock down 17% over the past three months, it is easy to disregard Cosmo Pharmaceuticals (VTX:COPN). However...
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
Cosmo Pharmaceuticals N.V. / Key word(s): AgreementCosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings 30.03.2023 / 06:00 GMT/BSTDublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansion of the license agreement for Lumeblue™ with China Medical System Holdings Limited (“CMS”) (SEHK: 867). The expansion goes beyond the existing licensed territories (Greater
With a price-to-earnings (or "P/E") ratio of 53.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...
Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results23-March-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 23 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reports full-year 2022 financial results for the year ended 31 December 2022. Financial highlights In 2022, Cosmo has overtaken the €100 million annual
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement22-March-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 22 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its fully owned subsidiary Cosmo Intelligent Medical Devices – IMD is expanding its cooperation with Medtronic, the world’s largest healt
Cosmo Pharmaceuticals N.V. / Key word(s): Annual ResultsInvitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023 16.03.2023 / 06:00 GMT/BSTDublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast
Cosmo Pharmaceuticals N.V. / Key word(s): Preliminary Results16-Feb-2023 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 16 February 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2022. Total revenues of €102.1m vs. guidance of €90m - €100m, representing
If you want to know who really controls Cosmo Pharmaceuticals N.V. ( VTX:COPN ), then you'll have to look at the makeup...
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement21-Dec-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Singapore – 21 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyphens Pharma International Limited (SGX: 1J5) (“Hyphens”) today announced the signing of License and Supply Agreements for Winlevi® (clasco
Cosmo Pharmaceuticals N.V. / Key word(s): Study resultsCosmo announces successful Phase III clinical trial of Lumeblue™ in China 14.12.2022 / 06:00 GMT/BST Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK). In the trial, Lumeblue™ was compared to placebo in white light colonoscopy with the purpo
Most readers would already be aware that Cosmo Pharmaceuticals' (VTX:COPN) stock increased significantly by 20% over...
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders should be happy to see the share price up 20% in the last month...
Cosmo Pharmaceuticals N.V. / Key word(s): Regulatory ApprovalCosmo announces FDA grants orphan-drug designation ofrifamycin for treatment of pouchitis 20.10.2022 / 06:00 GMT/BSTDublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.Patients with ulcerative colitis (UC) may require removal of their colon and rectum (proctocolectomy), and the surgi
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousGI Genius™ named to FORTUNE 2022 “Change the World” list 12.10.2022 / 06:00 GMT/BSTDublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that GI Genius™ intelligent endoscopy module has been named to the prestigious FORTUNE 2022 “Change the World” list.Today, the GI Genius™ module is the first commercially av
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousMedtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening 06.10.2022 / 06:15 GMT/BSTDublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release that it has been awarded a contract for its Gastrointe
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement04-Oct-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, It
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results28-Jul-2022 / 06:06 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement28-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Ko
Cosmo Pharmaceuticals N.V. / Key word(s): Agreement26-Jul-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary
Cosmo Pharmaceuticals N.V. / Key word(s): ConferenceInvitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022 06.07.2022 / 06:00 Dublin, Ireland – 6 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2022 results on Thursday, 28 July 2022 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CEST with Alessandro Dell
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous28-Jun-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland – 28 June 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices